Health & Safety Industry Today

Neurofibromatoses Type I Analysis, Study and Pipeline Review H1 2017

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Neurofibromatoses Type I - Pipeline Review, H1 2017”
Published 12 April 2018

Neurofibromatoses Type I

Summary 

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017

Report Highlights

The  Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

  Table of Contents 

List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview 
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development 
Pipeline Overview 
Pipeline by Companies 
Pipeline by Universities/Institutes 
Products under Development by Companies 
Products under Development by Universities/Institutes 
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment 
Assessment by Target 
Assessment by Mechanism of Action 
Assessment by Route of Administration 
Assessment by Molecule Type 
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development 
Alexion Pharmaceuticals Inc 
Array BioPharma Inc  .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Other Industry News

Ready to start publishing

Sign Up today!